Gold prices jumped to an eight-month high on Thursday, closing in on the key $1,900 /oz mark.
PharmaTher Announces Grant of U.S. Patent on Ketamine Formulation
Pharmather announces a method of use and composition of matter patent from the USPTO for its proprietary ketamine formulation, KETABET(TM).
Optimi Health Approved to Supply Psilocybin Under Health Canada’s Special Access Program
Optimi Health's subsidiary has been named an approved supplier of psilocybin for Health Canada's SAP access program.
Mindset Pharma Identifies New Pharmacological Insights of First Generation Psychedelics Through its COPE Program with InterVivo Solutions
Mindset announces new insights in research on psychedelics molecules via its COPE initiative.
Novamind Advances Clinical Pilot for Frontline KAP
Novamind announces a "clinical pilot" aimed at bringing ketamine-assisted therapy to treat the mental health disorders of frontline healthcare workers.
Field Trip Health Ltd. Reports Third Fiscal Quarter 2022 Financial Results and Provides Business Update
During the quarter, Field Trip progressed its strategy of building the leading psychedelic therapy company through its Field Trip Health division and continued to invest in its lead drug development program.
Hawaii Senators Approve Psilocybin Task Force Bill In Committee, With Decriminalization Measures Still Pending
A Hawaii Senate committee on Friday approved a bill to set up a state working group to study the therapeutic benefits of psilocybin mushrooms.
Price gains for gold, silver on safe-haven demand
Gold and silver futures prices are higher in early U.S. trading Monday, with gold notching a nearly three-month high.
Psychedelic Medicine For PTSD: The Key To U.S. Legal Reforms
There are many valid reasons to push forward with legal reforms to advance psychedelic medicine. In the U.S., however, it is the treatment of PTSD that is bringing Republicans and Democrats together.
Big Pharma In Psychedelics: Inside Mindset Pharma’s Deal With Otsuka
How interested are pharmaceutical companies in psychedelics? While some are hesitant to even discuss where they stand on this restricted class of drugs, a deal inked last month validates the path of at least one company developing next-generation psychedelics.
Cybin Inc. Reports Third Quarter Financial Results and Recent Business Highlights
Cybin announces its Q3 results, supported by a conference call. Cash as of December 31, 2021 of CAD$63.6 million.
Cybin Announces Grant of U.S. Patent Covering its Proprietary Compound CYB004 (Deuterated DMT) for the Treatment of Anxiety Disorders
Cybin announces receiving a composition of matter patent for its DMT-derived compound, CYB004 from the the USPTO.
